AbbVie Inc. (NYSE: ABBV) ended Tuesday, November 25, 2025, on a firmer footing, closing at $231.80, up about 1.0% on the day and recovering some of Monday’s pullback. The move came amid a flurry of fresh headlines: U.S. Medicare confirmed plans to negotiate prices on 15 expensive drugs including an AbbVie product, AbbVie launched a new biotech award program in Quebec, and analysts published both bullish and cautious takes on the stock’s valuation and growth prospects. [1]
Below is a full recap of AbbVie’s stock performance and all major ABBV-related news published on November 25, 2025, along with context for investors.
AbbVie stock price snapshot for 25 November 2025
According to end-of-day data, AbbVie shares: [2]
- Closed: $231.80
- Previous close: $229.51
- Daily change: +$2.29 (+1.0%)
- Intraday range: $230.31 – $234.08
- Volume: ~6.9 million shares (vs. a recent average around 6.4 million)
Over the past year, ABBV has traded between a 52‑week low of $164.39 and a 52‑week high of $244.81, putting today’s close roughly 5% below its high and about 41% above the low. [3]
MarketBeat data show: [4]
- Market cap: about $410 billion
- Trailing P/E: ~110 (inflated by one‑off charges)
- Forward P/E: ~16.7× at ~$231–232 per share (StockStory estimate)
- P/E/G ratio: ~1.4
- Beta: ~0.50 (less volatile than the broader market)
- Debt-to-equity ratio: ~44x (reflecting AbbVie’s acquisitive history and large debt stack)
- Institutional ownership: ~70%
On the analyst side, MarketBeat reports a “Moderate Buy” consensus rating, with two Strong Buys, thirteen Buys and ten Holds, and an average 12‑month price target of about $241.85—modest upside from today’s close. [5]
Key AbbVie headlines published on November 25, 2025
1. Medicare drug price negotiations capture AbbVie’s Linzess
The most market‑sensitive policy headline today came from Reuters, which reported that the U.S. government is preparing to announce negotiated prices for 15 of Medicare’s costliest medicines, with new prices scheduled to take effect in 2027. Among the drugs highlighted is Linzess, an irritable bowel syndrome treatment marketed in partnership with AbbVie. [6]
The article notes:
- The announcement of negotiated prices is expected by this Sunday.
- The new figures will apply starting in 2027 and are designed to deliver meaningful savings to Medicare beneficiaries.
- The program is part of broader efforts to align U.S. drug costs more closely with those in other wealthy countries. [7]
Implications for ABBV:
- Linzess is not AbbVie’s largest product, but inclusion in the negotiation list reinforces the long‑term pricing pressure facing big pharma, especially companies with large U.S. exposure.
- Pricing cuts in 2027 may slightly compress future margins on the product and could influence how investors model long‑run cash flows for AbbVie’s broader portfolio of mature drugs.
For today’s session, investors seemed to shrug off the distant 2027 effective date, with ABBV closing higher despite the headline.
2. AbbVie launches Biotech Innovators Award in Quebec
In more company‑specific news, AbbVie announced a new AbbVie Biotech Innovators Award in partnership with adMare BioInnovations to support early‑stage Canadian biotechnology companies in Quebec. [8]
Key details from the GlobeNewswire release and Fierce Biotech’s coverage: [9]
- The competition is national in scope but focused on Quebec‑based early‑stage biotechs.
- Targeted areas match AbbVie’s strategic focus: immunology, oncology, neuroscience, eye care and aesthetics.
- The winning company will receive:
- One year of free lab and office space at the adMare Innovation Centre in Quebec.
- Access to AbbVie’s scientific and business leaders for mentoring and insights.
- Applications are open until February 20, 2026. [10]
While the program is unlikely to move earnings in the near term, it underscores AbbVie’s strategy of tapping external innovation ecosystems rather than relying solely on in‑house R&D. For long‑term ABBV shareholders, this kind of initiative can help seed relationships with potential future partners or acquisition targets.
3. AbbVie named a “Best Health Care Stock to Buy for 2026”
On the bullish side, U.S. News & World Report, via WTOP, updated its list of the “10 Best Health Care Stocks to Buy for 2026”, placing AbbVie among the top names. [11]
CFRA analyst Sel Hardy highlights: [12]
- AbbVie’s key products Skyrizi and Rinvoq are expected to more than offset headwinds from Humira’s loss of exclusivity and changes to Medicare Part D.
- CFRA projects high single‑digit compound annual revenue growth through 2029.
- Combined revenue from Skyrizi and Rinvoq is projected to reach about $31 billion in 2027.
- CFRA rates AbbVie a “Buy” with a $275 price target, implying roughly 20% upside from the $229.51 close on November 24. [13]
This narrative reinforces the prevailing bull case: AbbVie’s post‑Humira transition is being led by an exceptionally strong immunology franchise, and the stock still appears reasonably valued relative to its growth outlook.
4. Dividend‑King reputation reaffirmed
A separate note from Seeking Alpha on “Best Dividend Kings: November 2025” points out that 19 Dividend Kings—including AbbVie—are outperforming the S&P 500 year‑to‑date, even though the group struggled in October. [14]
AbbVie is highlighted as one of the long‑term dividend stalwarts that: [15]
- Has delivered strong total returns in 2025 (Zacks estimates around 28% year‑to‑date share price appreciation vs. about 3% for its industry group).
- Continues to grow its payout, contributing to a 2025 dividend growth rate across Dividend Kings of around 5–6%.
On top of that, MarketBeat notes that AbbVie recently raised its quarterly dividend to $1.73 per share (annualized $6.92), implying roughly a 3.0% forward yield at today’s price. [16]
5. StockStory flags AbbVie as a stock to sell
Not all commentary was upbeat. A StockStory piece titled “1 Surging Stock with Exciting Potential and 2 Facing Challenges” singled out AbbVie as one of the two stocks to sell despite its climb toward 52‑week highs. [17]
Their concerns include: [18]
- Underwhelming constant‑currency revenue growth over the past two years, suggesting that some products may not be delivering enough volume relative to price.
- Rising expenses as a share of revenue, with adjusted operating margin reportedly shrinking by 11.4 percentage points over five years.
- Flat earnings per share over five years despite higher revenue, implying that incremental sales have been less profitable.
StockStory pegs AbbVie’s forward valuation at about 16.7× forward earnings based on a price around $231.59—roughly in line with many large‑cap pharma peers but, in their view, not sufficiently discounted given these margin and growth pressures. [19]
This is a useful counterweight to the more optimistic CFRA and Dividend King narratives: it emphasizes that profitability trends and cost discipline remain key watchpoints for ABBV investors.
6. Oncology branding push: “Second Winds” CLL film
On the marketing and brand‑building front, Fierce Pharma reported that AbbVie has released a short film titled “Second Winds”, spotlighting patients living with chronic lymphocytic leukemia (CLL). [20]
Key points: [21]
- The film follows three individuals who find renewed purpose after a CLL diagnosis.
- AbbVie’s oncology patient‑advocacy leadership describes the project as a way to “capture the real‑world experience” of people with serious diseases and strengthen patient‑to‑patient connection.
- The campaign ties directly into AbbVie’s CLL portfolio, which includes Imbruvica (a BTK inhibitor co‑marketed with Johnson & Johnson) and Venclexta, a BCL‑2 inhibitor developed with Roche.
While not a direct financial catalyst, this initiative supports brand equity around AbbVie’s cancer medicines and reflects the company’s ongoing investment in patient‑centric storytelling.
7. Quebec award coverage deepens innovation story
Beyond the raw press release, Fierce Biotech ran an in‑depth article on the AbbVie Biotech Innovators Award. It emphasizes that: [22]
- The award offers not just lab space but also executive‑level mentorship, signaling AbbVie’s desire to plug into Canada’s growing life‑sciences ecosystem.
- The first iteration of the award earlier this year went to Neuropeutics, a Toronto company working on neurodegenerative diseases, underscoring AbbVie’s interest in neuroscience beyond its current commercial portfolio.
For investors, this coverage shows AbbVie positioning itself as a partner of choice for early‑stage biotech, an avenue that can feed its long‑term pipeline via deals, options and acquisitions.
8. Gene‑therapy collaboration ABBV‑RGX‑314 highlighted
In a press release about an upcoming investor conference, REGENXBIO reminded the market about its collaboration with AbbVie on surabgene lomparvovec (ABBV‑RGX‑314), a gene therapy candidate for wet age‑related macular degeneration (AMD) and diabetic retinopathy. [23]
The PR reiterates that ABBV‑RGX‑314 is in late‑stage development and represents an important potential entry for AbbVie into the one‑time gene‑therapy space for retinal diseases. While no new data were released today, the renewed mention keeps this asset on investors’ radar as a medium‑term catalyst.
9. Politician and institutional investors trim ABBV holdings
Two separate MarketBeat articles highlighted selling activity by a U.S. Representative and a large asset manager: [24]
- Rep. Lisa C. McClain (R‑Michigan) disclosed the sale of between $1,001 and $15,000 of AbbVie stock on October 30, as part of a cluster of small stock sales across multiple companies. MarketBeat notes that ABBV shares were trading around $231.95 and up about 1.1% intraday today, with a consensus “Moderate Buy” and the average $241.85 price target. [25]
- Verity & Verity LLC, a U.S. investment firm, reported that it trimmed its AbbVie position by about 0.8% in Q2, selling 1,358 shares and bringing its holdings to 172,194 ABBV shares, worth roughly $31.96 million at the time. AbbVie still represents about 2.7% of the firm’s portfolio, remaining its fifth‑largest position. [26]
Both moves are small relative to overall trading volume and do not, in isolation, signal a material shift in sentiment, but they do feed into ongoing interest in how politicians and institutions trade large pharma names.
Fundamental backdrop: Q3 2025 beat, raised guidance and dividend hike
Today’s commentary builds on AbbVie’s strong third‑quarter 2025 results, released on October 31 and widely covered by Zacks and others. [27]
Highlights from Zacks’ analysis: [28]
- Q3 2025 adjusted EPS: $1.86, beating the consensus estimate of $1.77 and ahead of AbbVie’s own guidance range of $1.74–$1.78.
- Revenue: $15.78 billion, above the $15.59 billion consensus and up 9.1% year over year on a reported basis.
- Drivers:
- Immunology star drugs Skyrizi and Rinvoq posted revenue growth of about 46% and 34%, respectively.
- Neuroscience products, including Vraylar, Ubrelvy, Qulipta and new Parkinson’s therapy Vyalev, also delivered strong gains.
- Headwinds:
- Humira sales fell roughly 56% year over year, continuing their steep decline after the U.S. patent cliff.
- Aesthetics and eye‑care portfolios showed softer performance than expected.
AbbVie also raised its 2025 adjusted EPS guidance to $10.61–$10.65, up from $10.38–$10.58 previously, signaling management confidence in the strength of its growth drivers. [29]
MarketBeat further notes that AbbVie has: [30]
- Issued Q4 2025 EPS guidance of $3.32–$3.36.
- Increased its quarterly dividend from $1.64 to $1.73 per share, effective with the February 2026 payment.
Taken together, the Q3 beat, upgraded outlook and dividend hike underpin much of the bullish analyst sentiment seen in today’s CFRA/US News and Dividend King commentary, even as other voices like StockStory remain cautious on margins and long‑term profitability.
How today’s news fits into the AbbVie (ABBV) investment case
Putting all the November 25 headlines together, the picture for AbbVie stock looks like this:
Bullish forces
- Strong growth engines: Skyrizi, Rinvoq and key neuroscience products are driving robust top‑line growth and underpinning a raised 2025 EPS outlook. [31]
- Resilient income profile: AbbVie’s status as a Dividend King with a newly raised dividend and ~3% yield appeals to dividend and defensive investors. [32]
- Analyst support: CFRA’s $275 target and “Buy” rating, plus a MarketBeat consensus of “Moderate Buy” and a ~$242 average target, suggest the sell‑side still sees upside. [33]
- Innovation and pipeline breadth: The Quebec biotech award, gene‑therapy collaboration ABBV‑RGX‑314, and ongoing oncology and neuroscience M&A efforts all point to a broad, actively managed pipeline. [34]
Bearish and risk factors
- Margin and cost concerns: StockStory’s critique centers on margin compression and flat EPS over a five‑year period despite rising sales, underscoring the importance of cost discipline as AbbVie invests heavily in R&D and deals. [35]
- Regulatory overhang: Medicare’s upcoming price negotiations, including for Linzess, reinforce long‑term pricing pressure on branded drugs in the U.S. [36]
- High leverage: AbbVie’s high debt‑to‑equity ratio leaves it more sensitive to interest‑rate and refinancing conditions than some peers. [37]
- Erosion of legacy blockbusters: Humira’s steep decline and softer aesthetics performance show that some legacy profit centers are under sustained pressure. [38]
Net takeaways for ABBV as of November 25, 2025
- Valuation: Around 16–17× forward earnings with a nearly 3% dividend yield, AbbVie trades at a modest premium to some big pharma peers but arguably in line with its above‑average growth outlook. [39]
- Momentum: The stock is trading near its 52‑week high yet still below recent peaks, with year‑to‑date gains estimated near 28%. [40]
- Storyline: Today’s news flow largely reinforces the existing narrative: a high‑yield pharma giant successfully pivoting away from Humira, but now facing the next phase of challenges—regulatory pricing pressure, rising costs and the need to continually replenish its pipeline.
As always, this article is for information and news purposes only and does not constitute investment advice. Investors should consider their own risk tolerance, time horizon and portfolio needs, and may wish to consult a licensed financial adviser before making trading decisions.
References
1. stockanalysis.com, 2. stockanalysis.com, 3. www.marketbeat.com, 4. www.marketbeat.com, 5. www.marketbeat.com, 6. www.reuters.com, 7. www.reuters.com, 8. www.globenewswire.com, 9. www.globenewswire.com, 10. www.fiercebiotech.com, 11. wtop.com, 12. wtop.com, 13. wtop.com, 14. seekingalpha.com, 15. seekingalpha.com, 16. www.marketbeat.com, 17. markets.financialcontent.com, 18. markets.financialcontent.com, 19. markets.financialcontent.com, 20. www.fiercepharma.com, 21. www.fiercepharma.com, 22. www.fiercebiotech.com, 23. www.prnewswire.com, 24. www.marketbeat.com, 25. www.marketbeat.com, 26. www.marketbeat.com, 27. www.nasdaq.com, 28. www.nasdaq.com, 29. www.nasdaq.com, 30. www.marketbeat.com, 31. www.nasdaq.com, 32. seekingalpha.com, 33. wtop.com, 34. www.globenewswire.com, 35. markets.financialcontent.com, 36. www.reuters.com, 37. www.marketbeat.com, 38. www.nasdaq.com, 39. markets.financialcontent.com, 40. stockanalysis.com
